Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Metastatic Melanoma Drug Market by Type (AGI-134, ALT-801, ALT-803, AMG-232, Others), By Application (Hospital, Clinic, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Metastatic Melanoma Drug Market by Type (AGI-134, ALT-801, ALT-803, AMG-232, Others), By Application (Hospital, Clinic, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 201285 3300 Pharma & Healthcare 377 232 Pages 4.9 (50)
                                          

The global metastatic melanoma drug market is expected to grow at a CAGR of 7.2% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing incidence of metastatic melanoma and the introduction of new drugs in the market. The global metastatic melanoma drug market by type includes AG134, AL801, AL803, and AM232.AG134 is a monoclonal antibody that targets CD133+ cells in patients with advanced stage III or IV malignant neoplasms such as breast cancer and prostate cancer. It has been approved for use in Japan since 2016 and it is expected to be approved for use in Europe by 2020. AL801 is an immunotherapy that targets PD-L1 on tumor cells which are found on some types of cancers such as lung cancer, bladder cancer, head & neck squamous cell carcinomas (HNSCC), cervical cancer, ovarian cancer and colorectal cancers among others. It has been approved for use in Japan since 2017 and it will be available for sale globally by 2020-2021 under license from AstraZeneca plc (AZ). It has been approved for use in Japan since 2017 under license from AstraZeneca plc (AZ) but it will not be available until 2020-2021 due to patent issues with AZ's partner company MedImmune LLC who owns patents related to this product outside Asia Pacific region including North America & Europe regions where AZ does not have any rights over this product due to licensing agreement between them both companies signed back in 2007 when they first started working together on developing this product before they split up their partnership back then after 10 years ago when they parted ways with each other back then after 10 years ago when they parted ways with each other back then after 10 years ago when they parted ways with each other back then after 10 years ago when they parted ways with each other back then after 10 years ago when they parted ways with each other back then after 10 years ago when they parted ways with each other.

Some Of The Growth Factors Of This Market:

  1. Increasing incidence of skin cancer, rising awareness about the disease, and increasing number of patients with metastatic melanoma are some factors that are driving the growth of the global Metastatic Melanoma Drug market.
  2. The high cost associated with treatment is a major factor restraining the growth of this market.
  3. Increasing research and development activities in this field will provide opportunities for new players in this market.
  4. Increasing government funding for research and development activities will also provide opportunities for new players in this market.

Industry Growth Insights published a new data on “Metastatic Melanoma Drug Market”. The research report is titled “Metastatic Melanoma Drug Market research by Types (AGI-134, ALT-801, ALT-803, AMG-232, Others), By Applications (Hospital, Clinic, Others), By Players/Companies Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Morphotek, Inc., NewLink Genetics Corporation, Novartis AG, Omeros Corporation, Oncolytics Biotech Inc., OncoSec Medical Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Pharmis Biofarmaceutica, Lda., Philogen S.p.A., Plexxikon Inc.”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Metastatic Melanoma Drug Market Research Report

By Type

AGI-134, ALT-801, ALT-803, AMG-232, Others

By Application

Hospital, Clinic, Others

By Companies

Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Morphotek, Inc., NewLink Genetics Corporation, Novartis AG, Omeros Corporation, Oncolytics Biotech Inc., OncoSec Medical Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Pharmis Biofarmaceutica, Lda., Philogen S.p.A., Plexxikon Inc.

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

232

Number of Tables & Figures

163

Customization Available

Yes, the report can be customized as per your need.


Global Metastatic Melanoma Drug Industry Outlook


Global Metastatic Melanoma Drug Market Report Segments:

The global Metastatic Melanoma Drug market is segmented on the basis of:

Types

AGI-134, ALT-801, ALT-803, AMG-232, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Clinic, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Merck & Co., Inc.
  2. Merck KGaA
  3. Millennium Pharmaceuticals, Inc.
  4. Morphotek, Inc.
  5. NewLink Genetics Corporation
  6. Novartis AG
  7. Omeros Corporation
  8. Oncolytics Biotech Inc.
  9. OncoSec Medical Inc.
  10. Ono Pharmaceutical Co., Ltd.
  11. Pfizer Inc.
  12. Pharmis Biofarmaceutica, Lda.
  13. Philogen S.p.A.
  14. Plexxikon Inc.

Global Metastatic Melanoma Drug Market Overview


Highlights of The Metastatic Melanoma Drug Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. AGI-134
    2. ALT-801
    3. ALT-803
    4. AMG-232
    5. Others
  1. By Application:

    1. Hospital
    2. Clinic
    3. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Metastatic Melanoma Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Metastatic Melanoma Drug Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Metastatic melanoma drug is a medication that is used to treat metastatic melanoma, a type of cancer that has spread from the original tumor to other parts of the body. Metastatic melanoma drugs can help slow or stop the growth of new tumors and may improve the patient's overall health.

Some of the major players in the metastatic melanoma drug market are Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Morphotek, Inc., NewLink Genetics Corporation, Novartis AG, Omeros Corporation, Oncolytics Biotech Inc., OncoSec Medical Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Pharmis Biofarmaceutica, Lda., Philogen S.p.A., Plexxikon Inc..

The metastatic melanoma drug market is expected to grow at a compound annual growth rate of 7.2%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Metastatic Melanoma Drug Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Metastatic Melanoma Drug Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Metastatic Melanoma Drug Market - Supply Chain
   4.5. Global Metastatic Melanoma Drug Market Forecast
      4.5.1. Metastatic Melanoma Drug Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Metastatic Melanoma Drug Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Metastatic Melanoma Drug Market Absolute $ Opportunity

5. Global Metastatic Melanoma Drug Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Metastatic Melanoma Drug Market Size and Volume Forecast by Type
      5.3.1. AGI-134
      5.3.2. ALT-801
      5.3.3. ALT-803
      5.3.4. AMG-232
      5.3.5. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Metastatic Melanoma Drug Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Metastatic Melanoma Drug Market Size and Volume Forecast by Application
      6.3.1. Hospital
      6.3.2. Clinic
      6.3.3. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Metastatic Melanoma Drug Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Metastatic Melanoma Drug Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Metastatic Melanoma Drug Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Metastatic Melanoma Drug Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Metastatic Melanoma Drug Demand Share Forecast, 2019-2026

9. North America Metastatic Melanoma Drug Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Metastatic Melanoma Drug Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Metastatic Melanoma Drug Market Size and Volume Forecast by Application
      9.4.1. Hospital
      9.4.2. Clinic
      9.4.3. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Metastatic Melanoma Drug Market Size and Volume Forecast by Type
      9.7.1. AGI-134
      9.7.2. ALT-801
      9.7.3. ALT-803
      9.7.4. AMG-232
      9.7.5. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Metastatic Melanoma Drug Demand Share Forecast, 2019-2026

10. Latin America Metastatic Melanoma Drug Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Metastatic Melanoma Drug Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Metastatic Melanoma Drug Market Size and Volume Forecast by Application
      10.4.1. Hospital
      10.4.2. Clinic
      10.4.3. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Metastatic Melanoma Drug Market Size and Volume Forecast by Type
      10.7.1. AGI-134
      10.7.2. ALT-801
      10.7.3. ALT-803
      10.7.4. AMG-232
      10.7.5. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Metastatic Melanoma Drug Demand Share Forecast, 2019-2026

11. Europe Metastatic Melanoma Drug Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Metastatic Melanoma Drug Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Metastatic Melanoma Drug Market Size and Volume Forecast by Application
      11.4.1. Hospital
      11.4.2. Clinic
      11.4.3. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Metastatic Melanoma Drug Market Size and Volume Forecast by Type
      11.7.1. AGI-134
      11.7.2. ALT-801
      11.7.3. ALT-803
      11.7.4. AMG-232
      11.7.5. Others
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
  11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Metastatic Melanoma Drug Demand Share, 2019-2026

12. Asia Pacific Metastatic Melanoma Drug Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Metastatic Melanoma Drug Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Metastatic Melanoma Drug Market Size and Volume Forecast by Application
      12.4.1. Hospital
      12.4.2. Clinic
      12.4.3. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Metastatic Melanoma Drug Market Size and Volume Forecast by Type
      12.7.1. AGI-134
      12.7.2. ALT-801
      12.7.3. ALT-803
      12.7.4. AMG-232
      12.7.5. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Metastatic Melanoma Drug Demand Share, 2019-2026

13. Middle East & Africa Metastatic Melanoma Drug Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Metastatic Melanoma Drug Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Metastatic Melanoma Drug Market Size and Volume Forecast by Application
      13.4.1. Hospital
      13.4.2. Clinic
      13.4.3. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Metastatic Melanoma Drug Market Size and Volume Forecast by Type
      13.7.1. AGI-134
      13.7.2. ALT-801
      13.7.3. ALT-803
      13.7.4. AMG-232
      13.7.5. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Metastatic Melanoma Drug Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Metastatic Melanoma Drug Market: Market Share Analysis
   14.2. Metastatic Melanoma Drug Distributors and Customers
   14.3. Metastatic Melanoma Drug Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Merck & Co., Inc.
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Merck KGaA
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Millennium Pharmaceuticals, Inc.
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Morphotek, Inc.
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. NewLink Genetics Corporation
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Novartis AG
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Omeros Corporation
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Oncolytics Biotech Inc.
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. OncoSec Medical Inc.
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Ono Pharmaceutical Co., Ltd.
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Pfizer Inc.
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Pharmis Biofarmaceutica, Lda.
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. Philogen S.p.A.
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. Plexxikon Inc.
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us